Abstract:OBJECTIVE:To explore the risks of long-term proton pump inhibitors (PPI) use.METHODS:A total of 79 study subjects were selected from patients seeking health care at outpatient gastroenterology clinic at Peking University People's Hospital during January 2011 to June 2013. Long-term PPI use was defined as taking PPI for at least one year. They were divided into study (n = 79) and control (n = 47) groups after matching for age and gender. The study group had 43 females and 36 males with an average age of (63 ± 10) years. And the control group had 28 females and 19 males with an average age of (63 ± 9) years. Data collected were demographic characteristics, clinical diagnosis, detailed dosing information of PPI. serum hemochrome, serum gastrin, vitamin B(12), serum iron, magnesium, calcium, copper, zinc, bone density of hip joint and lumbar vertebra L(1-4). Statistic analysis was performed with SPSS software (t and χ(2) test).RESULTS:The medium duration of PPI use was 3.07(1-15) years. Daily usage was a full or half amount of pharmaceutical directed dosage. Questionnaires regarding appetite, defecation, infection, otalgia change in long-term PPI use indicated:among them, 77(97.5%) cases had no appetite change and 2 (2.5%) improved. And 73 cases (92.4%) had no change or 2 cases improved (2.5%) in bowel movements habits while another 4 cases (5.1%) changed into loose stools. Lung or intestinal infection was not found. No case had an onset of otalgia related with PPI intake. Among PPI users, 14 cases (17.7%) appeared to have gastric polyps. T value of total bone density of hip and inter-hip was -0.93 ± 1.04 and -0.61 ± 0.91 respectively in the study group. And both were lower than those in the control group (-0.44 ± 1.12, -0.19 ± 0.94; t = -2.49, -2.35; P = 0.014, 0.021). No statistical differences existed in T value of neck of hip, as well as total T value and T value of each L(1-4) between study and control groups (all P > 0.05). Higher serum Mg compared to control group ((1.03 ± 0.08) vs (0.97 ± 0.07) mmol/L, t = 4.13, P = 0.000). No difference of serum calcium, copper, iron, zinc, vitamin B(12), folic acid and Hb,MCV,MCH between study and control groups (all P > 0.05). Higher serum gastrin versus normal range and controls were found in the study group ((108 ± 28) vs 100 vs (79 ± 26) ng/L, t = 2.56, 5.78; both P < 0.05). Taking manual routine dosage have higher hip and lumbar osteoporosis than half-dosage, and bone density decreased and normal bone density ratios are lower(all P < 0.05).CONCLUSIONS:Long-term use of PPI with small or average dosage may slightly decrease hip density and increase serum gastrin. However, there is little effect on vitamin B(12) and minerals.

Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density

Proton pump inhibitors, bone and phosphocalcic metabolism

Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility: A Retrospective Study

[The Risks of Long-Term Proton Pump Inhibitors Use].

Sex-specific association of chronic proton pump inhibitor use with reduced bone density and quality

Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A Cross-Sectional Study

Long-term Use of Proton Pump Inhibitors is Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease

Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved

Proton pump inhibitor therapy and potential long-term harm

Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro

Hypomagnesaemia leading to parathyroid dysfunction, hypocalcaemia, and hypokalaemia as a complication of long-term treatment with a proton pump inhibitor — a literature review

Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors

Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?

Adverse reactions of proton pump inhibitors

Proton Pump Inhibitors and the Risk of Bone Fractures: A Systematic Review

Proton pump inhibitor use and bone fractures in patients with chronic kidney disease

PPI use is not associated with bone microarchitecture and strength assessed with HR-pQCT after three-years follow-up in patients visiting the Fracture Liaison Service

Long Term Risks of Proton Pump Inhibitor Administration: A Literature Review

The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture—results of a large observational cohort study

Relationship between proton pump inhibitors and the risk of fractures in the observational studies: a systematic review and Meta-analysis

Proton pump inhibitors: Understanding the associated risks and benefits of long-term use.